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MaOBJECTIVES This study aimed to investigate sympathetic nerve (SN) ultrastructural changes and hemodynamic and
pulmonary artery (PA) pathological improvements by pulmonary arterial denervation (PADN) in animals with pulmonary
arterial hypertension (PAH), as well as the underlying mechanisms.
BACKGROUND SNoveractivity plays a role inPAH.Previous studieshave reported short-term improvements in pulmonary
arterial pressure (PAP) and cardiac function by PADN, but PA remodeling and the associated mechanisms remain unclear.
METHODS Forty dogs were randomly (ratio of 1:3) assigned to the control (intra-atrial injection of N-dimethylacetamide,
3 mg/kg) and test (intra-atrial injection of dehydrogenized-monocrotaline, 3 mg/kg) groups. After 8 weeks, the animals
in the test group with a mean PAP >25 mm Hg (n ¼ 20) were randomized (ratio of 1:1) into the sham and PADN groups.
At 14 weeks, the hemodynamics, medial wall thickness and PA muscularization, and messenger ribonucleic acid expression
of genes in lung tissues were measured. Another 35 PAH dogs were used to measure the SN conduction velocity, electron
microscopic assessment, and nerve distribution.
RESULTS PADN induced signiﬁcant SN demyelination and axon loss and slowed SN conduction velocity over time, with
resulting profound reductions in the mean PAP (23.5  2.3 mm Hg vs. 33.7  5.8 mm Hg), pulmonary vessel resistance
(3.5  2.3 Wood units vs. 7.7  1.7 Wood units), medial wall thickness (22.3  3.3% vs. 30.4  4.1%), and full muscu-
larization (40.3  9.3% vs. 57.1  5.7%) and increased nonmuscularization (29.8  6.1% vs. 12.9  4.9%) compared with
the Sham group (all p < 0.001). PADN inhibited the messenger ribonucleic acid expression of genes correlated with
inﬂammation, proliferation, and vasoconstriction.
CONCLUSIONS PADN induces permanent SN injury and subsequent improvements in hemodynamics and PA
remodeling in animals with PAH through mechanisms that may be experimentally and clinically beneﬁcial.
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ABBR EV I A T I ON S
AND ACRONYMS
MWT = medial wall thickness
PA = pulmonary artery
PADN = pulmonary artery
denervation
PAH = pulmonary arterial
hypertension
PAP = pulmonary arterial
pressure
RV = right ventricle/ventricular
SN = sympathetic nerve
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2014P ulmonary arterial hypertension (PAH)is a diverse group of diseases char-acterized by progressive pulmonary
vascular remodeling and right ventricular
(RV) failure and deﬁned by a resting
mean pulmonary arterial pressure (mPAP)
$25 mm Hg (1–3). Current treatments are
limited to pharmacological vasodilation and
antiproliferation (4–7); however, persistent
pulmonary artery (PA) remodeling puts many
patients at risk of death (5–7).
The innervation of the PA is predo-
minantly sympathetic (8), and increasedsympathetic nerve (SN) activity and circulating cat-
echolamines (9–11) have been demonstrated in pa-
tients with PAH, suggesting that SN overactivation
plays a critical role in PAH. Trials targeting sympa-
thetic activation have been undertaken; however, in
contrast to left heart failure, nonselective beta-
blockers reduce exercise capacity and worsen he-
modynamics in patients with PAH (1,12,13). This
outcome may be explained by the complex inner-
vation of the PA and the variety of neurotransmitters
and cotransmitters delivered to the pulmonary
vasculature (8,14,15). Surgical denervation of the
pulmonary artery abolishes the increase in pulmo-
nary arterial pressure (PAP) induced by PA extension
in experimental models (16). This effect has also
been demonstrated using percutaneous pulmonary
artery denervation (PADN) to abolish balloon inﬂa-
tion–induced increases in PA pressure in a dog
model (17) and in patients with PAH (18). However,
little published data demonstrates the pathological
improvements and the associated mechanisms of
PADN (19). Accordingly, the current study aimed to
investigate: 1) whether PADN induces persistent SNSEE PAGE 2024injury; 2) whether hemodynamics improvements by
PADN are accompanied by a subsequent improve-
ment of PA remodeling; and 3) whether PADN re-
duces inﬂammation, abnormal proliferation, and
vasoconstriction, 3 major mechanisms that are
correlated with the progression of PA remodeling in
an experimental PAH model.
METHODS
EXPERIMENTAL ANIMALS. The study protocol was
approved by the Institutional Animal Care and Use
Committee, in accordance with the Guide for the Care
and Use of Laboratory Animals (National Research
Council). The animals had free access to food andwater and were housed in a room with a 12:12-h light-
dark cycle at 20C to 24C.
Forty adult beagle dogs ($3 months of age,
body weight 8 to 10 kg, Nanjing Medical University
Animal Laboratory) were randomly assigned to 2
groups after the ﬁrst hemodynamic measurement:
control (n ¼ 10, intra-atrial injection of N-dimethy-
lacetamide, 3 mg/kg) and test (n ¼ 30, intra-
atrial injection of dehydrogenized monocrotaline
[DHMCT], 3 mg/kg). Eight weeks after the injection,
repeat hemodynamic measurements were per-
formed. Animals in the test group with an mPAP >25
mm Hg were randomly divided into sham (n ¼ 10,
PADN catheter was positioned in the PA and con-
nected with a generator, but without ablation) and
PADN (n ¼ 10, PADN procedure was performed for all
animals). After an additional 6 weeks, the ﬁnal he-
modynamic measurement was performed, all ani-
mals were sacriﬁced, and all lung tissues with PA
vasculature were stored at 80C for pathological
and molecular studies. SN trunks of the PA from
another 41 animals with or without injection of
DHMCT were isolated for the measurement of sym-
pathetic nerve conduction velocity (SNCV) and
evaluation by electron microscopy (Figure 1).
HEMODYNAMIC MEASUREMENTS. The hemody-
namic measurements have been described previously
(17,18). Brieﬂy, at 14 weeks, a 7-F sheath was inserted
into the femoral vein, and a Swan-Ganz catheter
(Edwards Lifesciences, Irvine, California) was posi-
tioned at the distal PA.
PADN PROCEDURE. Following randomization, the
animals were treated with aspirin (900 mg/day) and
clopidogrel (300 mg/day). PADN has been described
previously (17) and modiﬁed in this study (Figures 2A
to 2C). Brieﬂy, a 7-F PADN catheter was positioned at
the conjunctional area between the distal main PA and
the ostial left PA. At each point, ablation was per-
formed with the following parameters: a temperature
of 45C to 50C, energy #10 W, and time of 120 s.
TYROSINE HYDROXYLASE IMMUNOSTAINING. The ani-
mals were killed with an intraperitoneal injection
of sodium pentobarbital (50 mg/kg). The PA with
its surrounding adipose and connective tissue was
cleared of blood via an intravascular phosphate-
buffered saline bolus and immediately ﬁxed with
4% paraformaldehyde for 24 h.
PA tissues were divided into 3 segments (the main
PA trunk, 5 mm in length, and the proximal right and
left PA, each 1 cm in length) and were sliced at a
thickness of 5 mm. PA slices were then counterstained
FIGURE 1 Study Flowchart
Eight weeks after the injection of dehydrogenized monocrotaline (DHMCT) (3 mg/kg),
animals with mean pulmonary arterial pressure (mPAP) >25 mm Hg were randomized into
the sham and pulmonary artery denervation (PADN) groups. Six weeks after the injection,
repeated hemodynamic measurements and pulmonary artery (PA) remodeling were per-
formed for all animals. Another 41 animals with or without injection of DHMCT were used
to measure the sympathetic nerve conduction velocity (SNVC) and for electron microscopic
(EM) assessments at different time points after PADN. IA ¼ intra-atrial; NDTLT ¼ N-
dimethylacetamide; RHC ¼ right heart catheterization; SN ¼ sympathetic nerve.
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2015with hematoxylin. The tissues were examined using a
Leica TSL laser confocal microscope (Leica Micro-
systems Inc., Bannockburn, Illinois), and the distance
from the nerve endings to the PA vessel walls was
measured.
3-DIMENSIONAL RECONSTRUCTION OF PA AND
SYMPATHETIC NERVES. All of the images of SN
staining with PA vessel walls were converted into
grayscale from RGB, repeat coded with Grim software
(Vision Co., Nanjing, China), and then imported into a
blender to build the frame of the 3-dimensional PA.
Then, all of the nerve endings were completely
combined with the 3-dimensional PA model.
MEASUREMENTS OF SNCV. Of the 35 dogs, 10 dogs
with mPAP #25 mm Hg and the remaining 25 animals
with PAH were then used for an SNCV measurement
and electron microscope assessment after PADN
(Figure 1). To exclude the effect of DHMCT on SNCV,
we measured SNCV in 6 normal animals without
injection of DHMCT.
Following thoracotomy, the PA adventitia was
carefully separated from the PA, with precautions
undertaken to avoid damaging the nerves. The PA
sympathetic nerves were isolated and connected to
stimulator (2 mm proximal to the injured site) and
sensor (2 mm distal to the injured site) probes with
aeration. The distance between the sensor and stim-
ulator probes varied from 10.0 to 17.2 mm. A digital
storage oscilloscope (Tektronix 2211, Madell Tech-
nology Co., Ontario, California) was used to record
the conduction times (3 to 5 V stimulation and 5 ms
duration).
ULTRASTRUCTURAL CHANGES IN THE SN. The SNs
were dissected (from the entry point, almost at the
ostium of the main PA, to 2 mm distal to the oriﬁce of
the left branch) for electron microscopy. The nerves
were immersed in ﬁxative (2.5% glutaraldehyde) and
incubated at 4C for 12 h. Each specimen was then
immersed in 2% osmium tetroxide for 2 h at 4C and
then dehydrated and embedded. Following poly-
merization, sections were cut and stained with uranyl
acetate and lead citrate. The SN morphology was
examined (JEM 1010, JEOL, Tokyo, Japan), and the
axon diameter and the thickness of the myelin sheath
in the SN were measured.
IMMUNOHISTOCHEMISTRY. Immunohistochemistry has
been described previously. In brief, parafﬁn-
embedded lung tissues were sectioned (5-mm thick-
ness). Deparafﬁnization, rehydration, and antigen
retrieval were performed on the slides. Endogenous
peroxidases, avidin, nonspeciﬁc protein binding,
and biotin were blocked. Then, the sections weretreated with polyclonal goat antimouse RELMa (1:200,
R&D Systems, Minneapolis, Minnesota) antibodies
overnight at 4C. Finally, the slides were treated with
rabbit antigoat biotinylated secondary antibodies,
followed by a horseradish peroxidase reagent (Vec-
tastain Elite ABC Kit, Vector Laboratories, Burlingame,
California) for 30 min each at room temperature.
ASSESSMENT OF PA REMODELING. PA remodeling
was assessed in a blinded fashion. Lung sections were
stained with hematoxylin and eosin. Double staining
for the von Willebrand factor and a-smooth muscle
actin was performed to evaluate the muscularization
of the pulmonary vessels. Then, peripheral vessels
FIGURE 2 PADN Procedure, Lumen Lesion, and SN Injury
Pulmonary artery (PA) angiography of the left anterior cranial (A) and anterior-posterior cranial (B) view conﬁrmed the position of the ostial left pulmonary
artery (LPA) (solid red circle), right pulmonary artery (RPA), lateral wall of the PA trunk (green line in B), and posterior wall of the LPA (dashed red line).
The conjunction point of the main pulmonary artery (MPA) trunk lateral wall and ostial LPA was site b (C). Sites a and c indicate the points located at the
level of the distal main PA, 2 mm from site b. Immediately after PADN, an intimal injury was very clearly visualized (black arrow in D) and was replaced by
scarring (E). Sympathetic nerves localized in the groove (dashed black arrows in F) are parallel to the left lateral wall of the distal MPA up to the oriﬁce of
the LPA (solid black arrows); when the nerves were removed from this groove, the injured segment induced by PADN (solid blue arrows in F) became
swollen. (G) The shortest distance (823 mm) between the nerve endings and the PA lumen at the distal PA. The 3-dimensional reconstruction shows the
distribution of the sympathetic nerve endings from the anterior-posterior view (H) and counter-clockwise rotation (I). Abbreviations as in Figure 1.
Zhou et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 5 , 2 0 1 5
PADN Improving PA Remodeling D E C E M B E R 2 8 , 2 0 1 5 : 2 0 1 3 – 2 3
2016
TABLE 1 Sympathetic Nerve Conduction Velocity, Axon Diameter, and Myelin Thickness






Normal animals 6 14.15  2.30 2.15  0.28 0.37  0.01
mPAP #25 mm Hg 10 40.33  5.08* 5.27  0.41† 1.13  0.03*
mPAP >25 mm Hg 25
Prior to PADN 5 48.07  4.77‡ 5.98  0.20‡ 1.62  0.05‡
After PADN 20
Post-PADN 5 37.99  3.33§ 4.75  0.48§ 0.87  0.06§
1 month 5 26.34  4.94k 3.53  0.29¶ 0.62  0.05¶
2 months 5 17.82  4.85¶ 3.51  0.33¶ 0.55  0.06¶
3 months 5 13.05  3.76 3.13  0.19 0.39  0.05
Values are mean  SD. *p< 0.001, compared with all groups; †p < 0.01, compared with prior to PADN group and
normal animals; ‡p < 0.001, compared with all subgroups in after PADN group; §p < 0.001, compared with 1, 2,
and 3 months groups; kp < 0.01, compared with mPAP#25 mm Hg, 2 months, and 3 months groups; ¶p < 0.05,
compared with the 3 months group.
mPAP ¼mean pulmonary arterial pressure; PADN ¼ pulmonary artery denervation; SNCV ¼ sympathetic nerve
conduction velocity.
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2017from each dog were analyzed under an Olympus-BHS
microscope (San Jose, California) attached to a
QImaging Retiga 4000RV digital camera (Surrey,
British Columbia, Canada). Muscularization was
classiﬁed as non-, partial, or full. The percentage of
medial wall thickness (%MWT) was calculated as: %
MWT ¼ ([external diameter  internal diameter]/
external diameter)  100.
REAL-TIME QUANTITATIVE POLYMERASE CHAIN
REACTION. Animal lung tissue was homogenized in
RLT buffer, total ribonucleic acid was extracted using
an RNeasy mini kit (Qiagen, Germantown, Maryland),
and real-time quantitative polymerase chain reaction
was performed according to the manufacturer’s
instructions.
STATISTICAL ANALYSIS. The continuous variables
are expressed as the mean  SD. A normality test forFIGURE 3 Ultrastructural Change, SNCV, Axon Diameter, and Myelin Thickness
Before PADN, the myelin appeared smooth, and the mean SNCV was 48.1 m/s (A to F), with a mean myelin thickness of 1.62 mm (G) and an axon
diameter of 5.98 mm (H). After the PADN procedure, the myelin thickness gradually decreased and was almost demyelinated by 3 months (SN).
This result is consistent with the reduction of SNCV and axon loss. Abbreviations as in Figure 1.
FIGURE 4 Hemodynamic Changes
(A) Injection of dehydrogenized monocrotaline induced a signiﬁcant increase in the mean and systolic pulmonary arterial pressure and the
pulmonary vessel resistance at 8 weeks, which continuously increased over time in the sham group, but decreased signiﬁcantly 6 weeks after
the pulmonary artery denervation (PADN) procedure. PADN was associated with a signiﬁcant reduction of right ventricular (RV) mass/(left
ventricle [LV] þ interventricular septum [ST]). Individual changes in the mean pulmonary arterial pressure (mPAP), pulmonary vessel resistance
(PVR), and cardiac output (CO) are shown in B.
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2018all of the continuous variables was performed using
the Kolmogorov-Smirnov and Shapiro-Wilk tests.
The differences in the continuous variables between
the 2 treatments were analyzed using a paired t test or
the Mann-Whitney U test when appropriate. Post-hoc
analysis using Bonferroni’s method was used to
compare the 3 groups. The categorical variables were
compared using the Fisher exact test. Statistical
signiﬁcance was deﬁned as a 2-sided p value <0.05.
All analyses were performed using the statistical
program SPSS version 19.0 (SPSS Institute Inc.,
Chicago, Illinois).
RESULTS
PAH MODEL AND MORTALITY. Eight weeks after in-
jection with DHMCT, the PAH model was successfullyestablished in 20 dogs (67%) in the test group. A total
of 4 deaths occurred after the second randomization,
with 3 in the sham group and 1 in the PADN group.
Finally, the sham group contained 7 dogs, and the
PADN group contained 9 animals.
PADN PROCEDURE. PADN was performed at 3 sites
(Figures 2A to 2C). The median procedural time was
7.5 min (interquartile range: 6 to 16 min). Immedi-
ately after PADN, the ablated sites were clearly
observed on the intima of the PA (Figure 2D); these
sites were sealed and replaced by a scar at 1 month
(Figure 2E). No procedure-related complications
occurred.
VISUAL ASSESSMENT OF SN INJURY. The noninjured
SN had a smooth surface (Figure 2F, dashed blue
Continued on the next page
FIGURE 4 Continued
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2019arrows). Immediately after PADN, the ablated segment
became swollen (Figure 2F, solid blue arrows), which
was in line with an intimal injury (Figure 2E).
DISTRIBUTION OF SYMPATHETIC NERVES. PA sym-
pathetic nerve bundles were localized in the groove
parallel to the left lateral side of the main PA trunk
(Figure 2F) and were mostly bifurcated into the
posterior wall of the main PA and LPA, with very
few in the anterior wall of the right PA. The
shortest distance from the nerves to the PA lumen
was 823 mm, and the longest distance was 4,148 mm
(Figures 2G to 2I).
SNCV MEASUREMENTS. SNCV was 14.15  2.30 m/s in
normal animals, 40.3 m/s in animals with anmPAP #25 mm Hg, and 48.1 m/s in animals with an
mPAP >25 mm Hg, respectively (Table 1, Figure 3A).
After the PADN procedure, the SNCV decreased very
rapidly over time (Figures 3B to 3F).
ELECTRON MICROSCOPIC ASSESSMENT OF SN.
Most nerve endings in animals with mPAP >25
mm Hg had smooth and relatively thick myelin
(Figures 3, left panels [SN]), with a mean myelin
thickness of 1.62 mm and a mean axon diameter of
5.98 mm (Figures 3G and 3H), signiﬁcantly higher than
those (5.27 and 1.13 xm, respectively) in animals with
mPAP #25 mm Hg (Table 1). After the PADN proce-
dure, the myelin sheath became noticeably thinner
and the vacuoles degenerated over time (Table 1),
with axon diameters signiﬁcantly decreased to 3.53








Week 0 148  25 147  15 150  17
Week 8 139  23* 159  21 159  22
Week 14 134  27† 160  22 159  24
RAP, mm Hg
Week 0 1.7  0.9 1.9  1.3 1.7  0.9
Week 8 2.0  1.0‡ 2.7  2.5§ 2.7  1.2
Week 14 1.9  0.9† 2.3  0.8k 3.2  0.9
RVSP, mm Hg
Week 0 32.0  3.7 32.7  7.1 32.4  7.0
Week 8 33.4  3.4† 49.0  4.0§ 49.1  6.8
Week 14 36.0  4.3† 44.9  6.9k 55.8  5.7
sPAP, mm Hg
Week 0 27.9  2.2 27.6  5.3 27.3  3.8
Week 8 29.9  2.3† 46.3  4.3§ 45.2  5.5
Week 14 32.2  3.0† 40.6  4.6k 52.1  6.6
mPAP, mm Hg
Week 0 15.3  2.2 15.3  3.0 14.4  3.6
Week 8 16.9  1.7† 27.7  1.9§ 28.6  2.2
Week 14 17.3  2.8† 23.5  2.3k 33.7  5.8
Cardiac output, l/min
Week 0 3.6  0.5 3.5  0.6 3.5  0.5
Week 8 3.4  0.7* 2.5  0.7 2.5  0.9
Week 14 3.3  0.8† 2.9  0.8k 2.0  0.6
PVR, Wood units
Week 0 2.6  0.5 2.6  0.9 2.7  0.5
Week 8 2.9  0.5† 5.9  0.6¶ 6.2  0.6
Week 14 3.1  0.5† 3.5  0.7# 7.7  0.7
MWT at week 14, % 11.8  1.2k 22.3  3.3k 30.4  4.1
Muscularization at week 14,
mean  SD of %
None 59.1  9.7† 29.8  6.1k 12.9  4.9
Partial 29.4  9.8 29.8  9.7 30.3  3.7
Fully 11.5  2.6† 40.3  9.3k 57.1  5.7
Values are mean  SD. *p ¼ 0.005 compared with the PADN and sham groups; †p < 0.001
compared with the PADN and sham groups; ‡p ¼ 0.008 compared with the PADN and sham
groups; §p < 0.05 compared with value measured at week 14; kp < 0.001 compared with the
sham group; ¶p < 0.01 compared with value at week 14; #p ¼ 0.005 compared with the sham
group.
mPAP ¼ mean pulmonary arterial pressure; MWT ¼ medial wall thickness; PA ¼ pulmonary
artery; PVR ¼ pulmonary vessel resistance; RAP ¼ right atrial pressure; RVSP ¼ right ventricular
systolic pressure; sPAP ¼ systolic pulmonary arterial pressure.
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2020mm at 1 month. By 3 months post-PADN, the myelin
sheath was almost invisible (Figure 3, left panels
[SN], Figure 3G), and the nerve endings became
demyelinated (Figure 3H).
HEMODYNAMIC CHANGE. The baseline hemody-
namic variables were similar among the 3 groups
(Figure 4A, Table 2) and were stably sustained in the
control group, but increased continuously in the
sham group during the 14-week follow-up period.
PADN was associated with signiﬁcant reductions of
mPAP, systolic pulmonary arterial pressure, and rightatrial pressure, and increased CO, leading to a sig-
niﬁcant reduction of pulmonary vessel resistance
compared with the sham group. Finally, RV hyper-
trophy, by means of the ratio of the RV mass/(left
ventricle þ septal), in the PADN group was signiﬁ-
cantly lower than in the sham group (Figure 4A).
The individual data of mPAP, pulmonary vessel
resistance, and CO are shown in Figure 4B.
PA REMODELING. The %MWT in the PADN group was
22.3  3.3%, signiﬁcantly lower than that in the sham
group (30.4  4.1%, p < 0.001) (Table 2, Figure 5A).
The rates of NM and full muscularization in the Sham
group were 12.9  4.9% and 57.1  5.7%, respectively,
signiﬁcantly different from the PADN group 29.8 
6.1% and 40.3  9.3%, respectively (all p < 0.001)
(Figure 5B). There was no signiﬁcant difference in
partial muscularization between the sham and PADN
(p ¼ 0.057) groups.
REAL-TIME QUANTITATIVE POLYMERASE CHAIN
REACTION. DHMCT-exposure was characterized by
overexpression of platelet-derived growth factor-
subunit B, ﬁbroblast growth factor-2, endothelin-1,
endothelial nitric oxide synthase, and monocyte
chemoattractant protein-1 (Figure 6). These alter-
ations were signiﬁcantly less in the treatment group.
DISCUSSION
This study reports, for the ﬁrst time, that: 1) the PADN
procedure induces severe SN injury characterized by
signiﬁcant SN demyelination, axon loss, and slowing
of SNCV over time; and 2) the PADN procedure results
in signiﬁcant improvements in hemodynamics and
simultaneous PA remodeling in an experimental
PAH model by inhibiting inﬂammation, abnormal
proliferation, and vasoconstriction of pulmonary
vascular beds.
The PA is surrounded by adventitia, which is
loosely organized (8). The pulmonary trunk receives
innervation starting with bundles of large nerve
trunks that diminish in size, so that at the level of
the arterioles, there is only a single ﬁber (14), as
conﬁrmed by initial studies identifying dense nerve
endings at the proximal and bifurcated areas (15).
We found nerves located in the conjunctional area
between the left lateral wall of the main PA trunk
and the ostial LPA. This anatomic structure sug-
gested the possibility of achieving percutaneous
ablation at these conjunctional sites via heat gener-
ated from the high-frequency alternating current
(20). The intimal lesions post-PADN were replaced
by scars 1 month after the procedure, without
thrombus formation.
FIGURE 5 Pulmonary Artery Remodeling
The smooth muscle layer appeared smooth and thin by hematoxylin and eosin (HE) and by von Willebrand Factor (vWF) and a–smooth
muscle actin (SMA) staining. In the sham group, the percentage of medial wall thickness increased (A), with a signiﬁcant reduction in
nonmuscularization (NM) and increase in full muscularization (FM) (B) compared with the pulmonary artery denervation (PADN) group.
PM ¼ partial muscularization.
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2021Myelin protects the axons from injury and pro-
motes the conduction of neuroelectrical stimuli (21).
However, there has been no data clearly showing the
changes in myelin and axon diameters of SN in the
presence of PH or systematic hypertension. Our re-
sults demonstrate for the ﬁrst time increased SNCV,
myelin, and axon diameters in a DHMCT-induced
PH model. From our results, SNCV in normal ani-
mals (no injection of DHMCT) was similar to previous
reports (22,23), but we also found increased SNCV in
animals without PAH (mPAP #25 mm Hg) after in-
jection of DHMCT, which might indicate that DHMCT
induced PAH via different mechanisms when
compared with chronic hypoxia-induced PAH (24)
and that 8-week follow-up was relatively shorter for
these non-PAH animals. Given the truth that a mon-
ocrotaline model does not truly mimic severe PH
as observed in humans (24–27), our results should be
interpreted cautiously.
One of the key issues with the PADN procedure
is whether permanent SN injury could be achieved by
the ablation. Herein, visual assessment conﬁrmed the
severe nerve injury induced by PADN, as evidenced
by severely swollen SN at the ablated segment.
Furthermore, electron microscopy demonstrated that
demyelination and axon loss of the SN startedimmediately after the PADN procedure, resulting in
a prolonged conduction time and the loss of nerve
potential amplitude. Those results clearly showed
the efﬁcacy of PADN in inducing persistent nerve
injury in the surrounding tissues of the PA.
The proliferation of PA smooth muscle cells, lead-
ing to the increased muscularization of tiny arterioles
and reduced vascular lumen, is the hallmark of PAH
(1–3,15). The reverse of this pathological process is the
primary endpoint of testing for potential therapies in
animal models (25,26). Previous data revealed that SN
overactivation was strongly correlated with the
severity and prognosis of PAH (9–11) and that nebi-
volol, a b1-antagonist and b2,3-agonist, caused a sig-
niﬁcant improvement of endothelial function and PA
remodeling in animals with monocrotaline-induced
PAH (27). Overstimulation of adrenergic b1-receptors
in PAH leads to vessel constriction caused by
impaired endothelial dysfunction, inﬂammation,
and oxidative stress (9,10,27). The profound reduc-
tion in the muscularization of the small PA after
PADN, as demonstrated by our study, is consistent
with the improvement in hemodynamics and might
be directly related to the SN injury induced by
ablation. However, nerves in the adventitia of the
PA and lung surrounding tissues consist of different
FIGURE 6 mRNA Expression Assessed by RT-qPCR
Dehydrogenized monocrotaline-induced pulmonary arterial
hypertension (PAH) animal models displayed a signiﬁcant
up-regulation of growth factors endothelin-1 (ET-1) (A),
endothelial nitric oxide synthase (eNOS), and monocyte chemo-
attractant protein (MCP)-1 (B). All of these changes were
signiﬁcantly improved by pulmonary artery denervation (PADN).
FGF ¼ ﬁbroblast growth factor; mRNA ¼ messenger ribonucleic
acid; PDGF-B ¼ platelet-derived growth factor-subunit B; RT-
qPCR ¼ real-time quantitative polymerase chain reaction.
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2022nervous ﬁbers (8,14,15), which release catechol-
amine, acetylcholine, histamine, neuropeptide-Y,
and others. These neurotransmitters and cotrans-
mitters are delivered to the pulmonary vasculature
and induce vessel constriction and proliferation of
smooth muscle cells (14,15). As a result, 1 positive
effect of PADN is the inhibition or block of most
(if not all) of the transmitters released from dif-
ferent nerves. However, a great deal of work
remains to be done to identify the complex mech-
anisms for PADN.
Molecular studies (7,26,27) have shown that growth
factors synthesized by many different cell types,
coupled with an increase of endothelial nitric oxide
synthase (causing endothelial dysfunction and
apoptosis resistance) (28–30), endothelin-1 (31), and
monocyte chemoattractant protein-1 (27), play an
important role in the pulmonary vascular remodeling
process responsible for the progression of PAH. Our
ﬁnding that PADN attenuates PA remodeling
by inhibiting abnormal cell growth is consistent witha previous study using nebivolol (26); however,
the latter study did not ﬁnd the reduction of ﬁbroblast
growth factor-2 after a high dose of nebivolol, indi-
cating that PADN, by inducing an injury to all nerves
(within reasonable distance of the vessel wall),
led to the blockage or inhibition of most (if not all)
transmitters released from the different nerves.
Nevertheless, further work is required to elucidate
the status of apoptosis resistance after the PADN
procedure.
CLINICAL RELEVANCE. PAH is a severe disease.
Sympathetic overactivation plays a critical role in
the process of PAH. Our study demonstrated the
improvements in hemodynamic, PA remodeling,
and cardiac function after the PADN procedure.
These beneﬁts of PADN for PAH patients need to be
testiﬁed by future clinical studies.
STUDY LIMITATIONS. First, the current study
selected beagle dogs to establish a PAH model
because the PADN catheter required a larger PA.
In contrast to studies using small animal models, the
success rate of establishing the PADN model in dogs
was relatively reduced (w70%). However, in the
present study, dogs with mPAP #25 mm Hg were
excluded from the study for PA remodeling. Next,
our study did not provide insights into the effect of
PADN on different transmitters and the protein
phosphorylation of signal molecules. However, our
preliminary data unmasked the mechanisms of PA
remodeling improvement by PADN. Third, the frac-
tion of inspired oxygen was not collected in this
study. Finally, the DHMCT-induced PAH model did
not represent human PAH in terms of pathological
changes (29). Further work will be required to test the
efﬁcacy of PADN in other PAH models.
CONCLUSIONS
Our results report that PADN induces SN injury
and improves hemodynamics and PA remodeling,
and provide the associated molecular mechanisms.
Further studies are required to ﬁne-tune the meth-
odology of the ablation and to elucidate the long-term
efﬁcacy in different PAH models.
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PERSPECTIVES
WHAT IS KNOWN? SN overactivity plays a critical role
in PAH. PADN was tested in experimental PAH and
patients.
WHAT IS NEW? Our results reported the improvement
and mechanisms of PA hemodynamic, remodeling, and
cardiac function after PADN.
WHAT IS NEXT? Further studies are required to conﬁrm
our ﬁnding.
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